All In Biotech

Drug Trial Radar · NCT06109649

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo

Last checked: Nov 20, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 11, 2023

Primary completion

Dec 2025

Study completion Jun 2026

Sponsor

Lead sponsor
Clinuvel, Inc.Industry
Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.

Conditions

  • Vitiligo

Interventions

  • Afamelanotide and NB-UVB LightDrug

    Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.

  • NB-UVB LightProcedure

    Patients will receive NB-UVB light twice per week for 20 weeks. Upon study completion, NB-UVB Light Arm participants will have the opportunity to enroll in an open-label extension phase of the study. In this extension phase, participants will undergo the same evaluations and assessments as the ones performed in the main part of the study under Afamelanotide and NB-UVB Light Arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients achieving T-VASI 50 on the bodyTime frame: From baseline to Day 140

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • CLINUVEL site

    Birmingham, Alabama

  • CLINUVEL site

    Fresno, California

  • CLINUVEL site

    Los Angeles, California

  • CLINUVEL site

    Palo Alto, California

  • CLINUVEL site

    San Diego, California

  • CLINUVEL Site

    Washington D.C., District of Columbia

  • CLINUVEL site

    Miami, Florida

  • CLINUVEL site

    Miramar, Florida

  • CLINUVEL site

    Alpharetta, Georgia

  • CLINUVEL site

    Augusta, Georgia

  • CLINUVEL site

    Chicago, Illinois

  • CLINUVEL site

    Baton Rouge, Louisiana

  • CLINUVEL site

    Detroit, Michigan

  • CLINUVEL site

    Minneapolis, Minnesota

  • CLINUVEL site

    Roseville, Minnesota

  • CLINUVEL Site

    Lee's Summit, Missouri

  • CLINUVEL site

    Rochester, New York

  • CLINUVEL site

    Cleveland, Ohio

  • CLINUVEL site

    Philadelphia, Pennsylvania

  • CLINUVEL Site

    Charleston, South Carolina

  • CLINUVEL site

    Thompson's Station, Tennessee

  • CLINUVEL Site

    Cedar Park, Texas

  • CLINUVEL site

    Dallas, Texas

  • CLINUVEL site

    Tyler, Texas

  • CLINUVEL site

    Charlottesville, Virginia

  • CLINUVEL site

    La Réunion, France

  • CLINUVEL site

    Nice, France

  • CLINUVEL site

    Nairobi, Kenya

  • CLINUVEL site

    London, United Kingdom

  • CLINUVEL site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.